CD52 and B-cell chronic lymphocytic leukemia: Alemtuzumab (anti-CD52, 3 μg/ml) was used as reference control since it is used for treatment of B cell chronic lymphocytic leukemia with manageable adverse events, also with respect to cytokine release [31, 32].